Copeptin: A biomarker of cardiovascular and renal function

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Morgenthaler, Nils G ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AQUAPORIN 2; ARGIPRESSIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; LOSARTAN; OXYTOCIN RECEPTOR; PROTEIN; SODIUM CHLORIDE; TOLVAPTAN; TROPONIN T; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOGENIC SHOCK; CARDIOVASCULAR FUNCTION; CONGESTIVE HEART FAILURE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; HYPONATREMIA; HYPOTENSION; KIDNEY FUNCTION; MICROALBUMINURIA; MORTALITY; NONHUMAN; PLASMA OSMOLALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; STROKE; SURVIVAL; WATER ABSORPTION; WATER DEPRIVATION;

ARGININE VASOPRESSIN; BIOLOGICAL MARKERS; BLOOD VOLUME; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GLYCOPEPTIDES; HEART FAILURE; HUMANS; KIDNEY; KIDNEY DISEASES; MYOCARDIAL INFARCTION; PROGNOSIS; ROC CURVE; SHOCK, CARDIOGENIC; STROKE; VASOPRESSINS;

EID: 77955168878     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00177.x     Document Type: Review

References (74)

1. Holwerda DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem 1972, 28:334-339.
2. Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982, 295:299-303.
3. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. peptides 2005, 26:2500-2504.
4. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119.
5. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008, 19:43-49.
6. Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci 2002, 18:223-228.
7. Repaske DR, Medlej R, Gultekin EK. Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1-->Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab 1997, 82:51-56.
8. Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 1982, 299:355-357.
9. Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 1983, 305:325-327.
10. Rivier C, Vale W. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo. Endocrinology 1983, 113:939-942.
11. Milsom SR, Conaglen JV, Donald RA. Augmentation of the response to CRF in man: relative contributions of endogenous angiotensin and vasopressin. Clin Endocrinol (Oxf) 1985, 22:623-629.
12. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000, 11:406-410.
13. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care 2003, 7:427-434.
14. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2 - clinical physiology. Crit Care 2004, 8:15-23.
15. Thibonnier M, Preston JA, Dulin N. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997, 138:4109-4122.
16. Peter J, Burbach H, Adan RA. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell Mol Neurobiol 1995, 15:573-595.
17. Thibonnier M, Conarty DM, Preston JA. Human vascular endothelial cells express oxytocin receptors. Endocrinology 1999, 140:1301-1309.
18. Gutkowska J, Jankowski M, Lambert C. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci U S A 1997, 94:11704-11709.
19. Zenteno-Savin T, Sada-Ovalle I, Ceballos G, Rubio R. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. Eur J Pharmacol 2000, 410:15-23.
20. Bhandari SS, Loke I, Davies JE. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009, 116:257-263.
21. Szinnai G, Morgenthaler NG, Berneis K. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007, 92(10):3973-3978.
22. Katan M, Morgenthaler NG, Dixit KC. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007, 92:2640-2643.
23. Fenske W, Stork S, Blechschmidt A. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009, 94:123-129.
24. Lindner KH, Strohmenger HU, Ensinger H. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology 1992, 77:662-668.
25. Krismer AC, Wenzel V, Stadlbauer KH. Vasopressin during cardiopulmonary resuscitation: a progress report. Crit Care Med 2004, 32:S432-S435.
26. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004, 30:1276-1291.
27. Wenzel V, Krismer AC, Arntz HR. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004, 350:105-113.
28. Dunser MW, Mayr AJ, Ulmer H. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003, 107:2313-2319.
29. Morgenthaler NG, Muller B, Struck J. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007, 28(6):644-649.
30. Arnauld E, Czernichow P, Fumoux F, Vincent JD. The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta). Pflugers Arch 1977, 371:193-200.
31. Khan SQ, Dhillon OS, O'Brien RJ. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007, 115:2103-2110.
32. Reichlin T, Hochholzer W, Stelzig C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009, 54:60-68.
33. Keller T, Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction. Circulation 2009, 120:S1035.
34. Jaffe AS, Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem 2010, 56:342-344.
35. CHOPIN. Copeptin helps in the early detection of patients with acute myocardial infarction. 2010, http://www.clinicaltrials.gov/ct2/show/NCT00952744?term=CHOPIN&rank=1
36. Schaller MD, Nicod P, Nussberger J. [Vasopressin in acute myocardial infarct: clinical implications]. Schweiz Med Wochenschr 1986, 116:1727-1729.
37. McAlpine HM, Morton JJ, Leckie B. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988, 60:117-124.
38. Donald RA, Crozier IG, Foy SG. Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction. Clin Endocrinol (Oxf) 1994, 40:499-504.
39. Charles CJ, Rogers SJ, Donald RA. Hypothalamo-pituitary-adrenal axis response to coronary artery embolization: an ovine model of acute myocardial infarction. J Endocrinol 1997, 152:489-493.
40. Katan M, Morgenthaler N, Widmer I. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008, 29:341-346.
41. Griebel G, Stemmelin J, Gal CS, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 2005, 11:1549-1559.
42. Henriksen JH, Moller S. Haemodynamics and fluid retention in liver disease. Ital J Gastroenterol Hepatol 1998, 30:320-332.
43. Griebel G, Simiand J, Stemmelin J. The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2003, 2:191-200.
44. Goldsmith SR. Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest Heart Fail 2002, 8:251-256.
45. Serradeil-Le Gal C, Wagnon J, Valette G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002, 139:197-210.
46. Rouleau JL, de Champlain J, Klein M. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993, 22:390-398.
47. Rouleau JL, Packer M, Moye L. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994, 24:583-591.
48. Stoiser B, Mortl D, Hulsmann M. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006, 36:771-778.
49. Gegenhuber A, Struck J, Dieplinger B. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007, 13:42-49.
50. Kelly D, Squire IB, Khan SQ. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008, 14:739-745.
51. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999, 195:93-98.
52. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987, 82:1213-1219.
53. Fan YH, Zhao LY, Zheng QS. Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci 2007, 81:327-335.
54. Konstam MA, Gheorghiade M, Burnett JC. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
55. Gheorghiade M, Konstam MA, Burnett JC. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
56. Wada K, Fujimori A, Matsukawa U. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2005, 507:145-151.
57. Neuhold S, Huelsmann M, Strunk G. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008, 52:266-272.
58. Voors AA, von Haehling S, Anker SD. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009, 30:1187-1194.
59. Katan M, Fluri F, Morgenthaler NG. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009, 66:799-808.
60. Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med 2003, 18:3-8.
61. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005, 98:529-540.
62. Hoorn EJ, Geary D, Robb M. Acute hyponatremia related to intravenous fluid administration in hospitalized children: an observational study. Pediatrics 2004, 113:1279-1284.
63. Bardoux P, Bichet DG, Martin H. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003, 18:497-506.
64. Fernandes S, Bruneval P, Hagege A. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 2002, 143:2759-2766.
65. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990, 258:F973-F979.
66. Sugiura T, Yamauchi A, Kitamura H. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999, 55:1800-1810.
67. Bardoux P, Bruneval P, Heudes D. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003, 18:1755-1763.
68. Meijer E, Bakker SJ, Halbesma N. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010, 77:29-36.
69. Cirillo M. Determinants of kidney dysfunction: is vasopressin a new player in the arena? Kidney Int 2010, 77:5-6.
70. Meijer E, Bakker SJ, de Jong PE. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009, 88:561-567.
71. Dunser MW, Schmittinger CA, Torgersen C. Copeptin and the transplanted kidney: friends or foes? Transplantation 2009, 88:455-456.
72. Golestaneh L, Talreja A, Le Jemtel TH. Vasopressin antagonists in heart failure. Curr Heart Fail Rep 2004, 1:190-196.
73. Schrier RW, Gross P, Gheorghiade M. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
74. Gerbes AL, Gulberg V, Gines P. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.